GentiBio engineers regulatory T-cells in novel biosynthetic ways to address serious unmet medical needs for auto-immunity, -inflammation and allergy patients.
✔️Christopher Moore, Director, will be presenting “An Allogeneic CD19-Targeted Engineered Treg Approach for Treating B Cell-Mediated Autoimmune Diseases” on Saturday, April 18 (2:30 PM)
We are excited to be presenting at the upcoming #AAI2026 next week and connecting with colleagues across the immunology community. Our team will be sharing both seminar presentations and poster sessions highlighting our latest advances in engineered regulatory T cell therapies.
✔️ Victoria DeVault-Nelson, Associate Director, will be presenting “Comprehensive Biomarker Strategy to Monitor GNTI-122, an Engineered Regulatory T Cell Therapy in Clinical Development to Treat Type 1 Diabetes” on Saturday, April 18 (2:30 PM)
GentiBio has successfully dosed the first participant in our clinical trial, the POLARIS Study, for adults recently diagnosed with Type 1 Diabetes (T1D). We are incredibly proud to announce this meaningful milestone for our team and community.
GentiBio announces preclinical data at #ESGCT showing antigen-specific engineered #Tregs suppressing pancreatic inflammation and potential utility for treatment and prevention of clinical type 1 #diabetes (#T1D)." Click here to learn more: https://t.co/QP8uKlFrbq
We’re thrilled to announce our collaboration with global leader @bmsnews to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with IBD. Read more here: https://t.co/zkMyRrGALu
Genti is happy to announce that Neely Mozaffarian, MD, PhD has joined as Chief Medical Officer. Please join us in welcoming Neely!
https://t.co/fYxUompR2y
GentiBio is thrilled to share a perspective piece on how to succeed. Our CEO, Adel Nada, discusses, in order to succeed you need to prepare for failure and the importance of learning from mistakes. Enjoy! https://t.co/VyCSsiIk7o
Congratulations to our fellow @NewEnglandVC#NEVYs21 Nominees –we're so proud to be nominated alongside this group of superheroes! December
2nd we will be at the @HOBBoston for the 9th Annual NEVY Awards, and we hope you’ll join us! https://t.co/fuxH3wPArB
Following the successful closing of a $157 million Series A, @GentiBio will continue to develop and advance its potential functional cure for #T1D to the clinic, alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation. https://t.co/eIH9obyr7m